Lurasidone Explained

Width:250
Width2:250
Alt2:Ball-and-stick model of the lurasidone molecule
Tradename:Latuda, others
Dailymedid:Lurasidone
Pregnancy Au:B1
Pregnancy Au Comment:[1]
Routes Of Administration:By mouth
Class:Atypical antipsychotic
Atc Prefix:N05
Atc Suffix:AE05
Legal Au:S4
Legal Au Comment:[2]
Legal Br:C1
Legal Br Comment:[3]
Legal Ca:Rx-only
Legal Uk:POM
Legal Uk Comment:[4]
Legal Us:Rx-only
Legal Us Comment:[5]
Legal Eu:Rx-only
Legal Status:Rx-only
Bioavailability:9–19% (oral)[6]
Protein Bound:~99%
Metabolism:Liver (CYP3A4-mediated)
Elimination Half-Life:18–40 hours
Excretion:Faecal (67–80%),
renal (9–19%)
Cas Number:367514-87-2
Pubchem:213046
Iuphar Ligand:7461
Drugbank:DB08815
Chemspiderid:184739
Unii:22IC88528T
Kegg:D04820
Chebi:70735
Chembl:1237021
Synonyms:SM-13496
Iupac Name:(3aR,4S,7R,7aS)-2-hexahydro-4,7-methano-2H-isoindole-1,3-dione
C:28
H:36
N:4
O:2
S:1
Smiles:C1CC[C@H]([C@@H](C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)[C@H]6[C@@H]7CC[C@@H](C7)[C@H]6C5=O
Stdinchi:1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1
Stdinchikey:PQXKDMSYBGKCJA-CVTJIBDQSA-N
Melting Point:176
Melting High:178
Solubility:0.224
Specific Rotation:[α]20D −59°

Lurasidone, sold under the brand name Latuda among others, is an antipsychotic medication used to treat schizophrenia and bipolar disorder.[7] It is taken by mouth.

Common side effects include sleepiness, movement disorders, nausea, and diarrhea.[7] Serious side effects are valid for all atypical antipsychotics and may include the potentially permanent movement disorder tardive dyskinesia, as well as neuroleptic malignant syndrome, an increased risk of suicide, angioedema, and high blood sugar levels,[8] although lurasidone is less likely to cause high blood sugar levels in most patients, hyperosmolar hyperglycemic syndrome may occur.[7] [9] [10] In older people with psychosis as a result of dementia, it may increase the risk of dying.[7] Use during pregnancy is of unclear safety.[11] [12]

Lurasidone was first approved for medical use in the United States in 2010.[7] In 2013, it was approved in Canada, and by the United States Food and Drug Administration, to treat bipolar depression, either as monotherapy or adjunctively with lithium or valproate.[13] [14] Generic versions were approved in the United States in 2019, and became available in 2023.[15] In 2021, it was the 193rd most commonly prescribed medication in the United States, with more than 2million prescriptions.[16] [17]

Medical uses

Lurasidone is used to treat schizophrenia and bipolar disorder.[7] [18] In bipolar disorder, It has been studied both as a monotherapy and adjunctive treatment to lithium or valproate.[19]

The European Medicines Agency approved lurasidone for the treatment of schizophrenia for people aged 13 years and older,[20] but not for bipolar disorder. In the United States, it is used to treat schizophrenia for people aged 13 years and older, as well as depressive episodes of bipolar disorder age 10 and over as a monotherapy, and in conjunction with lithium or valproate in adults.[21]

In July 2013, lurasidone received approval for bipolar I depression.[22] [23]

In June 2020, lurasidone was approved in Japan, eight years after its first approval in the United States.[24] In Japan it is approved for bipolar depression and schizophrenia.[25] [26] [27]

Few available atypical antipsychotics are known to possess antidepressant efficacy in bipolar disorder (with the notable exceptions being cariprazine,[28] quetiapine,[29] [30] [31] [32] olanzapine[33] [34] [35] and possibly asenapine[36]) as a monotherapy, even though the majority of atypical antipsychotics are known to possess significant antimanic activity,[37] which is yet to be clearly demonstrated for lurasidone.

In the early post approval period lurasidone-treated patients with bipolar disorder were retrospectively found to have more complex clinical profiles, comorbidities, and prior treatment history compared to patients initiated with other atypical antipsychotics. The study authors suggest this may be due to "the overall clinical profile of lurasidone, the role perceived for lurasidone in the therapeutic armamentarium by practitioners, and the recent introduction of lurasidone into clinical practice during the study period."[38]

Lurasidone is not approved by the Food and Drug Administration (FDA) for the treatment of behavior disorders in older adults with dementia.[39]

Contraindications

Lurasidone is contraindicated in individuals who are taking strong inhibitors of the liver enzyme CYP3A4 (ketoconazole, clarithromycin, ritonavir, levodropropizine, etc.) or inducers (carbamazepine, St. John's wort, phenytoin, rifampicin etc.).[40] The use of lurasidone in pregnant women has not been studied and is not recommended; in animal studies, no risks have been found.[41] Excretion in breast milk is also unknown; lurasidone is not recommended for breastfeeding women.[42] In the United States it is not indicated for use in children.[43] The enzyme CYP3A4 is involved in the digestion of drugs. Inhibitors such as grapefruit juice block its function resulting in too much drug in the body.[44]

Side effects

See also: List of adverse effects of lurasidone.

Side effects are generally similar to other antipsychotics. The drug has a relatively well tolerated side effect profile, with low propensity for QTc interval changes,[45] [46] weight gain and lipid-related adverse effects.[47] In a 2013 meta-analysis of the efficacy and tolerability of 15 antipsychotic drugs it was found to produce the second least (after haloperidol) weight gain, the least QT interval prolongation, the fourth most extrapyramidal side effects (after haloperidol, zotepine and chlorpromazine) and the sixth least sedation (after paliperidone, sertindole, amisulpride, iloperidone and aripiprazole).[48]

As with other atypical neuroleptics, lurasidone should be used with caution in the elderly because it puts them at an increased risk for a stroke or transient ischemic attack;[49] however, these risks are not likely to be greater than those associated with antipsychotics of other classes.[50] Similarly, lurasidone should not be used to treat dementia-related psychosis, as evidence has shown increased mortality with antipsychotic use.[51]

Weight gain is reported in up to 15 and 16 percent of users.[52] [53] Other possible side effects include vomiting, akathisia, dystonia, parkinsonism, somnolence, dizziness, sedation and nausea.[54] [55]

Discontinuation

The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotics to avoid acute withdrawal syndrome or rapid relapse.[56] Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite.[57] Other symptoms may include restlessness, increased sweating, and trouble sleeping.[57] Less commonly there may be a feeling of the world spinning, numbness, or muscle pains.[57] Symptoms generally resolve after a short period of time.[57]

There is tentative evidence that discontinuation of antipsychotics can result in psychosis.[58] It may also result in reoccurrence of the condition that is being treated.[59] Rarely tardive dyskinesia can occur when the medication is stopped.[57]

Interactions

Blood plasma concentrations may be increased when combined with CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, ritonavir, and voriconazole) possibly leading to more side effects. This has been clinically verified for ketoconazole, which increases lurasidone exposure by a factor of 9, and is also expected for other 3A4 inhibitors such as grapefruit juice. Co-administration of CYP3A4 inducers like rifampicin, carbamazepine or St. John's wort can reduce plasma levels of lurasidone and its active metabolite, and consequently decrease the effects of the drug. For rifampicin, the reduction was sixfold in a study.

Pharmacology

Pharmacodynamics

Lurasidone[60]
Site Ki (nM) Action Species Ref
>1,000
>1,000
6.75Partial agonistRat [61]
2.03AntagonistRat
415 Pig
>1,000
>1,000
0.5AntagonistHuman [62]
47.9Rat
41AntagonistHuman
10.8AntagonistHuman
>1,000
>1,000
262
1.68AntagonistRat
15.7Antagonist
30
>1,000 Guinea pig
>1,000 Human
Values are Ki (nM). The smaller the value, the more strongly the drug binds to the site.

Lurasidone [(3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl) piperazin-1-ylmethyl]-cyclohexylmethyl}-hexahydro-4,7-methano-2Hisoindole-1,3-dione hydrochloride] ][63]

Notes and References

  1. Web site: Lurasidone (Latuda) Use During Pregnancy . Drugs.com . 5 February 2020 . 12 May 2020 . 15 October 2020 . https://web.archive.org/web/20201015003725/https://www.drugs.com/pregnancy/lurasidone.html . live .
  2. Web site: Prescription medicines: registration of new chemical entities in Australia, 2014 . Therapeutic Goods Administration (TGA) . 21 June 2022 . 10 April 2023 . 10 April 2023 . https://web.archive.org/web/20230410065838/https://www.tga.gov.au/resources/resource/guidance/prescription-medicines-registration-new-chemical-entities-australia-2014 . live .
  3. Web site: Anvisa . Brazilian Health Regulatory Agency . 31 March 2023 . RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial . Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control. live . https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 . 3 August 2023 . 16 August 2023 . . pt-BR . 4 April 2023.
  4. Web site: Latuda 18.5mg film-coated tablets - Summary of Product Characteristics (SmPC) . (emc) . 16 January 2019 . 12 May 2020 . 14 October 2020 . https://web.archive.org/web/20201014042307/https://www.medicines.org.uk/emc/product/3299/smpc . live .
  5. Web site: Latuda- lurasidone hydrochloride tablet, film coated . DailyMed . 12 May 2020 . 28 August 2021 . https://web.archive.org/web/20210828152242/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afad3051-9df2-4c54-9684-e8262a133af8 . live .
  6. Web site: Product information Latuda (lurasidone hydrochloride). TGA eBusiness Services. Therapeutic Goods Administration. 28 October 2022. 28 October 2022. PDF. 28 October 2022. https://web.archive.org/web/20221028140222/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2020-PI-01864-1. live.
  7. Web site: Lurasidone Hydrochloride Monograph for Professionals . 21 March 2019 . Drugs.com . American Society of Health-System Pharmacists . 21 March 2019 . https://web.archive.org/web/20190321104507/https://www.drugs.com/monograph/lurasidone-hydrochloride.html . live .
  8. Web site: IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR LATUDA . 3 December 2022 . Latuda . 3 December 2022 . https://web.archive.org/web/20221203173914/https://www.latuda.com/sz/important-safety-information.html . live .
  9. Zhang Y, Liu Y, Su Y, You Y, Ma Y, Yang G, Song Y, Liu X, Wang M, Zhang L, Kou C . The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis . BMC Psychiatry . 17 . 1 . 373 . November 2017 . 29162032 . 5698995 . 10.1186/s12888-017-1539-0 . free .
  10. Hanyu S, Kojima Y, Murai T, Kawashima H . Lurasidone-induced hyperosmolar hyperglycemic syndrome: A case report . Neuropsychopharmacology Reports . 42 . 3 . 377–379 . September 2022 . 35609885 . 9515717 . 10.1002/npr2.12259 .
  11. Book: British national formulary: BNF 76 . 2018. Pharmaceutical Press. 978-0-85711-338-2. 393–394. 76.
  12. Web site: Lurasidone (Latuda) tablets for the treatment of schizophrenia in adults . 30 April 2020 . 27 February 2021 . https://web.archive.org/web/20210227005246/https://www.sps.nhs.uk/wp-content/uploads/2015/03/final20draft.pdf . dead .
  13. Bawa R, Scarff JR . Lurasidone: a new treatment option for bipolar depression-a review . Innovations in Clinical Neuroscience . 12 . 1–2 . 21–23 . 2015 . 25852975 . 4382136 .
  14. Pikalov A, Tsai J, Mao Y, Silva R, Cucchiaro J, Loebel A . Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment . International Journal of Bipolar Disorders . 5 . 1 . 9 . December 2017 . 28168632 . 5332323 . 10.1186/s40345-017-0075-7 . free .
  15. Web site: Generic Latuda Availability . Drugs.com . 30 April 2020 . 14 August 2020 . https://web.archive.org/web/20200814051621/https://www.drugs.com/availability/generic-latuda.html . live .
  16. Web site: The Top 300 of 2021 . ClinCalc . 14 January 2024 . 15 January 2024 . https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx . live .
  17. Web site: Lurasidone - Drug Usage Statistics . ClinCalc . 14 January 2024.
  18. Swann AC, Fava M, Tsai J, Mao Y, Pikalov A, Loebel A . Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis . CNS Spectrums . 22 . 2 . 228–235 . April 2017 . 28300012 . 10.1017/S1092852917000232 . 24653390 . free .
  19. Ali Z, Tegin C, El-Mallakh RS . Evaluating lurasidone as a treatment option for bipolar disorder . Expert Opinion on Pharmacotherapy . 21 . 3 . 253–260 . February 2020 . 31957501 . 10.1080/14656566.2019.1695777 . 210829608 .
  20. Web site: Latuda (lurasidone) An overview. European Medicines Agency, 2020 . 6 October 2022 . 6 October 2022 . https://web.archive.org/web/20221006100102/https://www.ema.europa.eu/en/documents/overview/latuda-epar-medicine-overview_en.pdf . live .
  21. Book: National Center for Biotechnology Information, U.S. National Library of Medicine . Key Limitations . https://www.ncbi.nlm.nih.gov/books/NBK195617/ . Lurasidone Hydrochloride (Latuda): Management of Manifestations of Schizophrenia . Canadian Agency for Drugs and Technologies in Health . 30 April 2020 . 2014 . Canadian Agency for Drugs and Technologies in Health . 28 August 2021 . https://web.archive.org/web/20210828152213/https://www.ncbi.nlm.nih.gov/books/NBK195617/ . live .
  22. Web site: Lowes R . Lurasidone Approved for Bipolar Depression . Medscape . 2013 . 1 October 2013 . 2 October 2013 . https://web.archive.org/web/20131002013831/http://www.medscape.com/viewarticle/807204 . live .
  23. Bawa R, Scarff JR . Lurasidone: a new treatment option for bipolar depression-a review . Innovations in Clinical Neuroscience . 12 . 1–2 . 21–23 . 2015 . 25852975 . 4382136 .
  24. Web site: Latuda to Finally Hit Japan Market on June 11 . 10 October 2022 . PHARMA JAPAN . en . 10 October 2022 . https://web.archive.org/web/20221010040006/https://pj.jiho.jp/article/242267 . live .
  25. Web site: Sumitomo Dainippon Pharma Announces Approval of Atypical Antipsychotic Agent, LATUDA Tablets in Japan . IR News Investor Relations . Sumitomo Pharma . 10 October 2022 . en . 10 October 2022 . https://web.archive.org/web/20221010040007/https://www.sumitomo-pharma.com/ir/news/2020/20200325-1.html . live .
  26. Web site: Kusuri-no-Shiori(Drug Information Sheet) Latuda tablets . 10 October 2022 . en . 10 October 2022 . https://web.archive.org/web/20221010040006/https://www.rad-ar.or.jp/siori/english/search/result?n=43474 . live .
  27. Okubo R, Hasegawa T, Fukuyama K, Shiroyama T, Okada M . Current Limitations and Candidate Potential of 5-HT7 Receptor Antagonism in Psychiatric Pharmacotherapy . Frontiers in Psychiatry . 12 . 623684 . 2021 . 33679481 . 10.3389/fpsyt.2021.623684 . free . 7930824 .
  28. Ragguett RM, McIntyre RS . Cariprazine for the treatment of bipolar depression: a review . Expert Review of Neurotherapeutics . 19 . 4 . 317–323 . April 2019 . 30753085 . 10.1080/14737175.2019.1580571 .
  29. Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, Paulsson B, Brecher M . A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I) . The Journal of Clinical Psychiatry . 71 . 2 . 150–162 . February 2010 . 20122369 . 10.4088/JCP.08m04995gre . EMBOLDEN I (Trial 001) Investigators .
  30. Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D . Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression . Journal of Affective Disorders . 121 . 1–2 . 106–115 . February 2010 . 19903574 . 10.1016/j.jad.2009.10.007 . Trisha Suppes .
  31. 10.1111/j.1399-5618.2008.00585.x . Corrigendum . 2008 . Bipolar Disorders . 10 . 3 . 451. free .
  32. Thase ME . Quetiapine monotherapy for bipolar depression . Neuropsychiatric Disease and Treatment . 4 . 1 . 11–21 . February 2008 . 18728771 . 2515925 . 10.2147/ndt.s1162 . free .
  33. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A . Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression . Archives of General Psychiatry . 60 . 11 . 1079–1088 . November 2003 . 14609883 . 10.1001/archpsyc.60.11.1079 . free .
  34. Tohen M, Katagiri H, Fujikoshi S, Kanba S . Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies . Journal of Affective Disorders . 149 . 1–3 . 196–201 . July 2013 . 23485111 . 10.1016/j.jad.2013.01.022 .
  35. Corya SA, Perlis RH, Keck PE, Lin DY, Case MG, Williamson DJ, Tohen MF . A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression . The Journal of Clinical Psychiatry . 67 . 5 . 798–806 . May 2006 . 16841630 . 10.4088/JCP.v67n0514 .
  36. Azorin JM, Sapin C, Weiller E . Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses . Journal of Affective Disorders . 145 . 1 . 62–69 . February 2013 . 22868059 . 10.1016/j.jad.2012.07.013 .
  37. Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, Purgato M, Spineli LM, Goodwin GM, Geddes JR . Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis . Lancet . 378 . 9799 . 1306–1315 . October 2011 . 21851976 . 10.1016/S0140-6736(11)60873-8 . 25512763 .
  38. Tohen M, Ng-Mak D, Rajagopalan K, Halpern R, Chuang CC, Loebel A . Patient Characteristics Associated With Use of Lurasidone Versus Other Atypical Antipsychotics in Patients With Bipolar Disorder: Analysis From a Claims Database in the United States . The Primary Care Companion for CNS Disorders . 19 . 3 . June 2017 . 28590601 . 10.4088/PCC.16m02066 .
  39. Web site: Lurasidone. MedlinePlus . U.S. National Library of Medicine . 11 September 2018. 23 January 2019. https://web.archive.org/web/20190123012938/https://medlineplus.gov/druginfo/meds/a611016.html. live.
  40. Chiu YY, Ereshefsky L, Preskorn SH, Poola N, Loebel A . Lurasidone drug-drug interaction studies: a comprehensive review . Drug Metabolism and Drug Interactions . 29 . 3 . 191–202 . 2014 . 24825095 . 10.1515/dmdi-2014-0005 . free .
  41. [Pregnancy category]
  42. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation . Obstetrics and Gynecology . 111 . 4 . 1001–1020 . April 2008 . 18378767 . 10.1097/AOG.0b013e31816fd910 . ACOG Committee on Practice Bulletins--Obstetrics .
  43. Moore TA . Schizophrenia treatment guidelines in the United States . Clinical Schizophrenia & Related Psychoses . 5 . 1 . 40–49 . April 2011 . 21459738 . 10.3371/CSRP.5.1.6 .
  44. Web site: Office of the Commissioner. 14 July 2021 . Grapefruit Juice and Some Drugs Don't Mix . FDA . en.
  45. Oral H . 14 September 2018 . Lurasidone is not associated with risk of QTc prolongation . Clinical Research in Practice: The Journal of Team Hippocrates . 4 . 2 . 10.22237/crp/1536278400 . 53322344 . 2379-4550 . 15 November 2022 . 15 November 2022 . https://web.archive.org/web/20221115033741/https://digitalcommons.wayne.edu/crp/vol4/iss2/8/ . live .
  46. Javed A, Arthur H, Curtis L, Hansen L, Pappa S . Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia . Neurology and Therapy . 8 . 2 . 215–230 . December 2019 . 31098889 . 6858892 . 10.1007/s40120-019-0138-z .
  47. Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study . Dainippon Sumitomo Pharma . 26 August 2009 . 3 October 2016 . 14 May 2015 . https://web.archive.org/web/20150514205205/http://www.ds-pharma.com/pdf_view.php?id=170 . dead .
  48. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM . Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis . Lancet . 382 . 9896 . 951–962 . September 2013 . 23810019 . 10.1016/S0140-6736(13)60733-3 . 32085212 .
  49. Web site: Latuda. Drugs.com. 17 December 2010. 5 April 2019. https://web.archive.org/web/20190405041927/https://www.drugs.com/latuda.html. live.
  50. Herrmann N, Mamdani M, Lanctôt KL . Atypical antipsychotics and risk of cerebrovascular accidents . The American Journal of Psychiatry . 161 . 6 . 1113–1115 . June 2004 . 15169702 . 10.1176/appi.ajp.161.6.1113 .
  51. Web site: Sunovion Pharmaceuticals. Latuda Prescribing Information. 25 March 2014. 12 July 2018. https://web.archive.org/web/20180712172540/http://www.latuda.com/LatudaPrescribingInformation.pdf. live.
  52. Meyer JM, Mao Y, Pikalov A, Cucchiaro J, Loebel A . Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia . International Clinical Psychopharmacology . 30 . 6 . 342–350 . November 2015 . 26196189 . 4593468 . 10.1097/YIC.0000000000000091 .
  53. Ketter TA, Sarma K, Silva R, Kroger H, Cucchiaro J, Loebel A . Lurasidone in the Long-Term Treatment of Patients with Bipolar Disorder: A 24-Week Open-Label Extension Study . Depression and Anxiety . 33 . 5 . 424–434 . May 2016 . 26918425 . 5069590 . 10.1002/da.22479 .
  54. Zheng W, Cai DB, Yang XH, Li L, Zhang QE, Ng CH, Ungvari GS, Li XB, Ning YP, Xiang YT . Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials . Journal of Psychiatric Research . 103 . 244–251 . August 2018 . 10.1016/j.jpsychires.2018.06.005 . 29906709 . 49227958 .
  55. Kolli V, Walia A, Kinnan S . Food Matters: Reduction of Lurasidone-Induced Nausea With Meals . The Primary Care Companion for CNS Disorders . 21 . 2 . 18l02343 . March 2019 . 30869204 . 10.4088/PCC.18l02343 . 76666344 .
  56. Book: BMJ Joint Formulary Committee . British National Formulary . 57 . March 2009 . Royal Pharmaceutical Society of Great Britain . United Kingdom . 978-0-85369-845-6 . 192 . 4.2.1 . Withdrawal of antipsychotic drugs after long-term therapy should always be gradual and closely monitored to avoid the risk of acute withdrawal syndromes or rapid relapse..
  57. Book: Haddad PM, Dursun S, Deakin B . Adverse Syndromes and Psychiatric Drugs: A Clinical Guide . 2004 . OUP Oxford . 978-0-19-852748-0 . 207–216 . 8 May 2020 . 10 January 2023 . https://web.archive.org/web/20230110164012/https://books.google.com/books?id=CWR7DwAAQBAJ&pg=PA207 . live .
  58. Moncrieff J . Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse . Acta Psychiatrica Scandinavica . 114 . 1 . 3–13 . July 2006 . 16774655 . 10.1111/j.1600-0447.2006.00787.x . 6267180 .
  59. Book: Sacchetti E, Vita A, Siracusano A, Fleischhacker W . Adherence to Antipsychotics in Schizophrenia . 2013 . Springer Science & Business Media . 978-88-470-2679-7 . 85 . 8 May 2020 . 10 January 2023 . https://web.archive.org/web/20230110164029/https://books.google.com/books?id=odE-AgAAQBAJ&pg=PA85 . live .
  60. Web site: PDSP Ki Database . Psychoactive Drug Screening Program (PDSP) . Bryan Roth . Roth BL, Driscol J . University of North Carolina at Chapel Hill and the United States National Institute of Mental Health . 14 August 2017 . 28 August 2021 . https://web.archive.org/web/20210828152151/https://pdsp.unc.edu/databases/pdsp.php?knowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=lurasidone&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query . live .
  61. Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, Oki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M . Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity . The Journal of Pharmacology and Experimental Therapeutics . 334 . 1 . 171–181 . July 2010 . 20404009 . 10.1124/jpet.110.167346 . 12893717 .
  62. Tarazi FI, Riva MA . The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia . Expert Opinion on Drug Discovery . 8 . 10 . 1297–1307 . October 2013 . 23837554 . 10.1517/17460441.2013.815163 . 25838798 .
  63. Amerio A, Giacomini C, Fusar-Poli L, Aguglia A, Costanza A, Serafini G, Aguglia E, Amore M . Efficacy and Safety of Lurasidone in Children and Adolescents: Recommendations for Clinical Management and Future Research . Current Pharmaceutical Design . 27 . 39 . 4062–4069 . 2021 . 34348620 . 10.2174/1381612827666210804110853 . 236926992 .
  64. Fountoulakis KN, Gazouli M, Kelsoe J, Akiskal H . The pharmacodynamic properties of lurasidone and their role in its antidepressant efficacy in bipolar disorder . European Neuropsychopharmacology . 25 . 3 . 335–342 . March 2015 . 25596883 . 10.1016/j.euroneuro.2014.11.010 . 25628197 .
  65. Franklin R, Zorowitz S, Corse AK, Widge AS, Deckersbach T . Lurasidone for the treatment of bipolar depression: an evidence-based review . Neuropsychiatric Disease and Treatment . 11 . 2143–2152 . 19 August 2015 . 26316760 . 4547662 . 10.2147/NDT.S50961 . free .
  66. Samalin L, Ben Gharbia M, Garnier M, Llorca PM . [Short-term efficacy and safety of lurasidone in the treatment of schizophrenia] . fr . L'Encephale . 40 . 6 . 507–517 . December 2014 . 25453735 . 10.1016/j.encep.2014.10.009 . Short-term efficacy and safety of lurasidone in the treatment of schizophrenia .
  67. Lincoln J, Tripathi A . 2011 . Lurasidone for Schizophrenia . Current Psychiatry . 10 . 1 . 67–70 . 2 October 2016 . 3 October 2016 . https://web.archive.org/web/20161003063328/http://www.mdedge.com/currentpsychiatry/article/64162/schizophrenia-other-psychotic-disorders/lurasidone-schizophrenia . live .
  68. Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y . Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test . European Journal of Pharmacology . 572 . 2–3 . 160–170 . October 2007 . 17662268 . 10.1016/j.ejphar.2007.06.058 .
  69. Greenberg WM, Citrome L . Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature . Clinical Pharmacokinetics . 56 . 5 . 493–503 . May 2017 . 27722855 . 10.1007/s40262-016-0465-5 . 207485482 .
  70. Cruz MP . Lurasidone HCl (Latuda), an Oral, Once-Daily Atypical Antipsychotic Agent for the Treatment of Patients with Schizophrenia . P & T . 36 . 8 . 489–492 . August 2011 . 21935296 . 3171824 .
  71. Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti A . Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone . European Neuropsychopharmacology . 29 . 9 . 971–985 . September 2019 . 31255396 . 10.1016/j.euroneuro.2019.06.008 . 11585/714012 . 195699303 . free .
  72. Wong DF, Kuwabara H, Brašić JR, Stock T, Maini A, Gean EG, Loebel A . Determination of dopamine D₂ receptor occupancy by lurasidone using positron emission tomography in healthy male subjects . Psychopharmacology . 229 . 2 . 245–252 . September 2013 . 23649882 . 10.1007/s00213-013-3103-z . 253737308 .
  73. Web site: Latuda: EPAR – Product Information. European Medicines Agency. 14 April 2016. 27 February 2017. 21 August 2016. https://web.archive.org/web/20160821085044/http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002713/WC500164683.pdf. live.
  74. Web site: European Medicines Agency Assessment report Latuda International non-proprietary name: LURASIDONE Procedure No. EMEA/H/C/002713/0000 . 14 November 2022 . 14 November 2022 . https://web.archive.org/web/20221114022004/https://www.ema.europa.eu/en/documents/assessment-report/latuda-epar-public-assessment-report_en.pdf . live .
  75. Web site: Latuda: Prescribing Information. Psychotherapeutic Drugs. 17 December 2010. https://web.archive.org/web/20110628044842/http://psychotherapeuticdrugs.com/index.php/new-drug-approvals/latuda-lurasidone-hcl. 28 June 2011. dead.
  76. Web site: Leading Latuda through the crowd. 1 October 2011. Latuda was developed at an R&D facility established in Fort Lee, NJ, about eight years ago by Sunovion's Japanese parent Dainippon Sumitomo Pharma Co. (DSP).. 25 June 2017. 28 August 2018. https://web.archive.org/web/20180828170409/http://www.mmm-online.com/features/leading-latuda-through-the-crowd/article/213096/. live.
  77. Book: Synthesis of Best-Seller Drugs. Vardanyan R, Hruby V. 7 January 2016. Academic Press. Google Books. 978-0-12-411524-8. 4 September 2017. 11 April 2023. https://web.archive.org/web/20230411014520/https://books.google.com/books?id=A8oHBgAAQBAJ&pg=PA100. live.
  78. Web site: EXCLI Journal. 17 November 2016. https://web.archive.org/web/20161117142131/http://excli.de/vol13/Mauri_13102014_proof.pdf. 17 November 2016.
  79. Book: National Center for Biotechnology Information, U.S. National Library of Medicine . Summary of Pharmacoeconomic Submission . https://www.ncbi.nlm.nih.gov/books/NBK195609/ . Lurasidone Hydrochloride (Latuda): Management of Manifestations of Schizophrenia . Canadian Agency for Drugs and Technologies in Health . 30 April 2020 . 2014 . Canadian Agency for Drugs and Technologies in Health . 28 August 2021 . https://web.archive.org/web/20210828152151/https://www.ncbi.nlm.nih.gov/books/NBK195609/ . live .
  80. Carey H, Fondriest M . Cost-Savings From an Antipsychotic Tablet-Splitting Program . P & T . 42 . 6 . 384–393 . June 2017 . 28579725 . 5440099 .
  81. News: Hopkins JS . Generic-Drug Approvals Soar, But Patients Still Go Without . 30 April 2020 . Wall Street Journal . 19 November 2019 . 27 April 2020 . https://web.archive.org/web/20200427084114/https://www.wsj.com/articles/many-generic-drugs-havent-hit-market-hindering-cost-control-efforts-11574198448 . live .
  82. Web site: 'Lurasidone' drug search. CIMS India. 21 April 2018. 28 August 2021. https://web.archive.org/web/20210828152153/https://www.mims.com/india/drug/search?q=Lurasidone. live.
  83. Web site: Generic Drugs (ndrugs.com). 30 April 2018. 1 May 2018. https://web.archive.org/web/20180501092921/https://www.ndrugs.com/?s=lurasidone#substitutes. live.
  84. Web site: Drug Approval Package: Latuda (lurasidone hydrochloride) Tablets NDA #200603 . U.S. Food and Drug Administration (FDA) . 24 December 1999 . 12 May 2020 . 25 February 2021 . https://web.archive.org/web/20210225053549/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200603Orig1s000TOC.cfm . live .
  85. FDA approves Latuda to treat schizophrenia in adults . U.S. Food and Drug Administration (FDA) . 28 October 2010 . https://web.archive.org/web/20101030233353/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm231512.htm . dead . 30 October 2010 . 29 October 2010.
  86. Web site: Latuda Supplement Approval Package 1 . U.S. Food and Drug Administration (FDA) . 12 May 2020 . 27 July 2020 . https://web.archive.org/web/20200727025352/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/200603Orig1s010.pdf . live .
  87. Web site: Latuda Supplement Approval Package 2 . U.S. Food and Drug Administration (FDA) . 12 May 2020 . 28 August 2021 . https://web.archive.org/web/20210828152150/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/200603Orig1s011.pdf . live .
  88. Web site: Scottish Medicines Consortium. 2014. Lurasidone, 18.5mg, 37mg, 74mg film-coated tablets (Latuda) SMC No. (994/14). scottishmedicines.org.uk. 7 March 2016. 8 March 2016. https://web.archive.org/web/20160308113939/http://www.scottishmedicines.org.uk/files/advice/lurasidone__Latuda__FINAL_Sept_2014_amended_15.09.14_for_website.pdf. dead.
  89. Web site: Latuda EPAR . European Medicines Agency (EMA) . 17 September 2018 . 12 May 2020 . 11 August 2020 . https://web.archive.org/web/20200811111331/https://www.ema.europa.eu/en/medicines/human/EPAR/latuda . live .
  90. Web site: Summary Basis of Decision (SBD) for Latuda. hc-sc.gc.ca. Health Canada. 2012. 19 June 2013. 27 June 2013. https://web.archive.org/web/20130627090950/http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2012_latuda_145406-eng.php#a2. live.
  91. Web site: European Marketing Authorization for Latuda. takeda.com. 25 November 2015. https://web.archive.org/web/20171226234708/http://www.tpi.takeda.com/media/news-releases/2014/european-marketing-authorization-for-latuda/. 26 December 2017. dead.
  92. Web site: Lurasidone: FDA-Approved Drugs . U.S. Food and Drug Administration (FDA) . 12 May 2020 . 1 October 2020 . https://web.archive.org/web/20201001225140/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208049 . live .
  93. Web site: PubChem . U.S. National Library of Medicine . (3aR,4S,7R,7aS)-2-(1R,2R)-2-4-(1,2-Benzisothiazol-3-yl)-1-piperazinylmethyl]cyclohexylmethyl]hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione |url=https://pubchem.ncbi.nlm.nih.gov/compound/50918847 |access-date=2 December 2022 |language=en |archive-date=2 December 2022 |archive-url=https://web.archive.org/web/20221202230335/https://pubchem.ncbi.nlm.nih.gov/compound/50918847 |url-status=live }} is an azapirone derivative[63] and acts as an antagonist of the dopamine D2 and D3 receptors,[64] and the serotonin 5-HT2A and 5-HT7 receptors, and the α2C-adrenergic receptor, and as a partial agonist of the serotonin 5-HT1A receptor. It has moderate-affinity antagonism at α2C-adrenergic receptors; low to very low-affinity antagonism at α1A-adrenergic α2A-adrenergic receptors.[65]

    It has only low and likely clinically unimportant affinity for the serotonin 5-HT2C receptor, which may underlie its low propensity for appetite stimulation and weight gain.[66] [67] The drug also has negligible affinity for the histamine H1 receptor and the muscarinic acetylcholine receptors, and hence has no antihistamine or anticholinergic effects.[68] [69] Drowsiness (somnolence) side effect is not explained by its antagonist activity to histamine.[70] [71]

    The relationship between dose and D2 receptor occupancy levels were 41–43% for 10 mg, 51–55% for 20 mg, 63–67% for 40 mg, 77–84% for 60 mg, and 73–79% for 80 mg.[72]

    Pharmacokinetics

    Lurasidone is taken by mouth and has an estimated absorption rate of 9 to 19%. Studies have shown that when lurasidone is taken with food, absorption increases about twofold. Peak blood plasma concentrations are reached after one to three hours. About 99% of the circulating substance are bound to plasma proteins.[73] Efficacy data for lurasidone have been evaluated for doses of 20 mg to 120 mg daily

    Lurasidone is extensively metabolised by CYP3A4 leading to contraindication of both strong inhibitors as well as strong inducers of this enzyme,[74] but has negligible affinity to other cytochrome P450 enzymes. It is transported by P-glycoprotein and ABCG2 and also inhibits these carrier proteins in vitro. It also inhibits the solute carrier protein SLC22A1, but no other relevant transporters.[75]

    Main metabolism pathways are oxidative N-dealkylation between the piperazine and cyclohexane rings, hydroxylation of the norbornane ring, and S-oxidation.:59 Other pathways are hydroxylation of the cyclohexane ring and reductive cleavage of the isothiazole ring followed by S-methylation. The two relevant active metabolites are the norbornane hydroxylation products called ID-14283 and ID-14326, the former reaching pharmacologically relevant blood plasma concentrations. The two major inactive metabolites are the N-dealkylation products (the carboxylic acid ID-20219 and the piperazine ID-11614), and a norbornane hydroxylated derivative of ID-20219 (ID-20220). Of lurasidone and its metabolites circulating in the blood, the native drug makes up 11%, the main active metabolite 4%, and the inactive carboxylic acids 24% and 11%, respectively. Several dozen metabolites have been identified altogether.:59–61

    Biological half-life is given as 18 hours or 20 to 40 hours in different sources. 80% or 67% of a radiolabelled dose was recovered from the feces, and 9% or 19% from the urine.

    History

    Lurasidone was first synthesised circa 2003.[76]

    Lurasidone is a structural analogue of ziprasidone. Lurasidone shows a very close pharmacological profile and has been synthesized similarly to ziprasidone.[77]

    Lurasidone is chemically similar to perospirone (also a chemical analogue of ziprasidone), as well as risperidone, paliperidone and iloperidone.[78]

    It has approval from the US Food and Drug Administration (FDA) for treating schizophrenia since 2010, and for treating depressive episodes in adults with bipolar I disorder since 2013.

    Society and culture

    Cost

    In Canada, as of 2014, lurasidone is generally more expensive than risperidone and quetiapine but less expensive than aripiprazole.[79]

    In the US, because a number of doses have the same price per tablet, pill splitting has been used to decrease costs.[80] In 2019, generic versions were approved in the United States; however, they only became available in 2023 due to drug patents.[81]

    Brand names

    In India, this drug is available under the brand names of Atlura, Lurace, Lurafic, Luramax (Sun Pharma), Lurasid, Lurastar, Latuda, Lurata[82] and additionally as Alsiva, Emsidon, Lurakem, Luratrend, Tablura, and Unisidon.[83]

    Regulatory approval

    Lurasidone was approved in the United States for the treatment of schizophrenia in October 2010[84] [85] and for the treatment of depressive episodes associated with bipolar I disorder in June 2013.[86] [87] It received regulatory approval in the United Kingdom in September 2014. In October 2014, NHS Scotland advised use of lurasidone for schizophrenic adults who have not seen improvements with previous antipsychotics due to problems that arise from weight gain or changes in metabolic pathways when taking other medications.[88] The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for it in January 2014, and it was approved for medical use by the EMA in March 2014.[89] It was launched in Canada for the treatment of schizophrenia in September 2012, Health Canada giving their Summary Basis of Decision (SBD) as favourable on 15 October 2012.[90] European Commission has granted a marketing authorization for once-daily oral lurasidone for the treatment of schizophrenia in adults.[91] It is approved for use in the EU.

    Generic versions of lurasidone were approved for use in the United States in January 2019, and became available in 2023.[92]

    External links

    .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Lurasidone".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.